In this month’s edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter, I’ll be addressing the following question in my new video Q&A: What is the best time to restart a patient on ruxolitinib after allogeneic stem cell transplantation?
Make sure to also watch video Q&As from previous editions, which focus on molecular mutations in MPNs and best practices for managing iron deficiency in polycythemia vera. Want your question featured in the next newsletter? Email it to email@example.com.
I’d also like to showcase a particularly helpful resource from our MPN Resources Center: ClinicalTrials.gov. Clinical trials are always a great option for MPN patients, and there are many studies currently enrolling. Take a look at ClinicalTrials.gov to see if your patient qualifies for any ongoing trials, and discuss them as a potential treatment option.
Last but not least, this month we feature some of the latest news and research in the field of MPNs, including important abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Please feel free to share this newsletter and our enduring resources with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at firstname.lastname@example.org at any time.
Lindsey Lyle, MS, PA-C
Senior Instructor, Blood Cancers and Bone Marrow Transplant Program
University of Colorado, Anschutz Medical Campus